These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15747208)

  • 21. Integrated nested services: Delaware's experience treating minority substance abusers at risk for HIV or HIV positive.
    Dillard D; Bincsik AK; Zebley C; Mongare K; Harrison J; Gerardi KE; Parcher DW
    J Evid Based Soc Work; 2010 Jan; 7(1):130-43. PubMed ID: 20178030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity.
    Chen S; Barnett PG; Sempel JM; Timko C
    J Subst Abuse Treat; 2006 Jul; 31(1):95-105. PubMed ID: 16814015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The costs of pursuing accreditation for methadone treatment sites: results from a national study.
    Zarkin GA; Dunlap LJ; Homsi G
    Eval Rev; 2006 Apr; 30(2):119-38. PubMed ID: 16492995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The business of addiction treatment: A research agenda.
    Kimberly JR; McLellan AT
    J Subst Abuse Treat; 2006 Oct; 31(3):213-9. PubMed ID: 16996384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs and benefits of combining probation and substance abuse treatment.
    Alemi F; Taxman F; Baghi H; Vang J; Thanner M; Doyon V
    J Ment Health Policy Econ; 2006 Jun; 9(2):57-70. PubMed ID: 17007484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year trajectories of health care utilization and cost in a drug and alcohol treatment sample.
    Parthasarathy S; Weisner CM
    Drug Alcohol Depend; 2005 Nov; 80(2):231-40. PubMed ID: 15916868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The medicalization of addiction treatment professionals.
    Roy AK; Miller MM
    J Psychoactive Drugs; 2012; 44(2):107-18. PubMed ID: 22880538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Decisions in case of "problematic" cost-effectiveness ratios based on the example of a clinical trial in rehabilitation care].
    Leidl R; Jacobi E; Knab J; Schweikert B
    Gesundheitswesen; 2006 Apr; 68(4):249-56. PubMed ID: 16705561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A research agenda for economic evaluation of substance abuse services.
    French MT; Drummond M
    J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic benefit of chemical dependency treatment to employers.
    Jordan N; Grissom G; Alonzo G; Dietzen L; Sangsland S
    J Subst Abuse Treat; 2008 Apr; 34(3):311-9. PubMed ID: 17614238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A large network of integrated medical care: the example of Kaiser Permanente in California. First-hand report by a physician].
    Aelony Y; Tschopp JM
    Rev Med Suisse; 2007 Feb; 3(99):484-6, 488. PubMed ID: 17424800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spirituality, sense of coherence, and coping responses in women receiving treatment for alcohol and drug addiction.
    Arévalo S; Prado G; Amaro H
    Eval Program Plann; 2008 Feb; 31(1):113-23. PubMed ID: 17825910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration demands highest standard of care.
    Brys S
    Behav Healthc; 2014; 34(2):26, 28. PubMed ID: 24864546
    [No Abstract]   [Full Text] [Related]  

  • 36. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders.
    Brunette MF; Mueser KT; Drake RE
    Drug Alcohol Rev; 2004 Dec; 23(4):471-81. PubMed ID: 15763752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation for ophthalmologists.
    Kuper H; Jofre-Bonet M; Gilbert C
    Ophthalmic Epidemiol; 2006 Dec; 13(6):393-401. PubMed ID: 17169853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington.
    French MT; Salomé HJ; Krupski A; McKay JR; Donovan DM; McLellan AT; Durell J
    Eval Rev; 2000 Dec; 24(6):609-34. PubMed ID: 11151519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of osteoporosis from the socioeconomic perspectives].
    Tanaka K
    Clin Calcium; 2006 Sep; 16(9):1536-41. PubMed ID: 16951480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.